Mark Arnold Hagler, Chief Commercial Officer of NovaBridge Biosciences, filed a Form 4 on November 19, 2026, disclosing two open-market purchases of Ordinary Shares on November 17 and November 18, 2026.
Key Highlights
- First purchase: 46,000 Ordinary Shares (represented by 20,000 ADSs) acquired on November 17, 2026, at a converted price of $0.343 per Ordinary Share ($0.79 per ADS).
- Second purchase: 184,000 Ordinary Shares (represented by 80,000 ADSs) acquired on November 18, 2026, at a converted weighted average price of $0.381 per Ordinary Share ($0.8758 per ADS).
- Price range on second purchase: ADSs were purchased at prices ranging from $0.84 to $0.90 per ADS, inclusive, across multiple transactions.
- Resulting ownership: Following the two transactions, Hagler directly held 460,000 Ordinary Shares, according to the filing.
- ADS conversion ratio: Each 10 ADSs represent 23 Ordinary Shares of the issuer, as disclosed in the filing's footnotes.
- Reporting person role: Mark Arnold Hagler is identified as Chief Commercial Officer of NovaBridge Biosciences (NASDAQ:NBP).
NovaBridge Biosciences CCO Hagler Discloses Two-Day Share Purchase Activity
According to the Form 4 filed with the U.S. Securities and Exchange Commission on November 19, 2026, Mark Arnold Hagler, Chief Commercial Officer of NovaBridge Biosciences (NASDAQ:NBP), reported two separate open-market purchases of the company's Ordinary Shares. Both transactions used transaction code "P," indicating open-market purchases, and both are recorded as directly held securities.
On November 17, 2026, Hagler acquired 46,000 Ordinary Shares represented by 20,000 American Depositary Shares at a converted price of $0.343 per Ordinary Share. The filing notes this figure represents a converted price from the ADS sale price of $0.79. Following that transaction, the filing reported his beneficial ownership at 276,000 Ordinary Shares held directly.
On November 18, 2026, Hagler acquired an additional 184,000 Ordinary Shares, represented by 80,000 ADSs. The converted weighted average price per Ordinary Share was reported as $0.381, corresponding to a weighted average ADS price of $0.8758. The filing discloses that the November 18 ADSs were purchased in multiple transactions at prices ranging from $0.84 to $0.90 per ADS, inclusive, and that Hagler undertakes to provide full information on the number of shares purchased at each separate price within that range upon request. After this second purchase, his directly held Ordinary Shares totaled 460,000 according to the filing. No derivative securities transactions were reported. The form was signed by Charles Silberstein as attorney-in-fact on November 19, 2026.
What Was Disclosed
The filing disclosed two open-market purchases by NovaBridge Biosciences Chief Commercial Officer Mark Arnold Hagler on November 17 and 18, 2026, totaling 230,000 Ordinary Shares (represented by 100,000 ADSs), bringing his direct beneficial ownership to 460,000 Ordinary Shares.




Please wait processing your request...